"This is a beginning of the ideal individualized treatment for metastatic non-small-cell lung cancer," said Inoue. "Patients treated with gefitinib would live much longer, with better quality of life, than those treated with cytotoxic chemotherapy." 井上说：“这是一个理想的个体化治疗转移性非小细胞肺癌的开始。相对于化疗病人，用吉非替尼的病人将有更好的生活质量以及更长的存活时间。”
Dr. Norman H. Edelman, chief medical officer for the American Lung Association, described the Japanese effort as "an important finding that could change the practice of treating lung cancer." 美国肺协会首席医疗官博士诺曼·德曼，对日本所做的工作评价是："一项重要发现，可以改变治疗肺癌的实践。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
